A021602 Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Start Date: January 19, 2021

IRB Number: https://www.clinicaltrials.gov/ct2/show/NCT03375320

Condition/Disease: Cancer - Pancreatic

Principal Investigator: Ding Wang, MD

Purpose of Research: cancer, pancreatic, pancreatic cancer, neuroendocrine

Status: Accepting Participants

Phone: (313) 916-1784

Filter Results

Consent for Cookie Use